12:00 AM
 | 
Jan 19, 2004
 |  BioCentury  |  Tools & Techniques

The liver's the thing

Targeting drugs to specific organs is a much sought after ability. Metabasis Therapeutics Inc. says its HepDirect prodrug technology to deliver drugs to the liver attracted Merck & Co. Inc. to partner its small molecule hepatitis C virus compounds.

"Hepatitis C is obviously a good fit for our technology," said Metabasis Chairman and CEO Paul Laikind. "Merck had drugs that were very effective against the HCV virus but had limitations for use in patients. In one case it's poor ability to get the compound into the liver, and in another...

Read the full 440 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >